Related Experiment Videos
[Basic and clinical studies on ceftazidime in the pediatric field].
The Japanese Journal of Antibiotics
|March 1, 1984
Summary
Ceftazidime (CAZ) demonstrates potent activity against Gram-negative bacteria in pediatric patients, showing excellent clinical and microbiological outcomes. This cephalosporin antibiotic is effective in treating various infections with minimal side effects.
Area of Science:
- Pharmacology
- Microbiology
Context:
- Pediatric infections pose significant health challenges.
- Ceftazidime is a third-generation cephalosporin antibiotic.
Purpose:
- To evaluate the antibacterial activity and clinical efficacy of ceftazidime in pediatric patients.
- To determine the pharmacokinetic profile of ceftazidime following intravenous administration.
Summary:
- Ceftazidime exhibits strong in vitro activity against Gram-negative rods, including Pseudomonas aeruginosa, with MICs comparable or superior to other cephalosporins.
- Pharmacokinetic studies show predictable blood concentrations and a half-life of approximately 1.3 hours after IV administration.
- Clinical trials indicate a high success rate (94% excellent/good response) in pediatric patients with various infections, with eradication of causative bacteria in 14 out of 17 cases.
Impact:
- Ceftazidime is a valuable therapeutic option for treating Gram-negative bacterial infections in children.
- The study provides essential data on ceftazidime's efficacy and safety profile in a pediatric population.
- Findings support the use of ceftazidime for empirical or targeted therapy in pediatric infectious diseases.